Paper26765645
Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study.
Dumitriu B and 20 others. Lancet Haematol, 2016. Cited by 45 papers, by iCite.
Cite this record
ConductScience Library. Alemtuzumab in T-cell large granular lymphocytic leukaemia: interim results from a single-arm, open-label, phase 2 study. Papers, record 26765645. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26765645
- Disease
- T-cell large granular lymphocyte leukemia15 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antibodies, Monoclonal, Humanized | Major topic |
| Antineoplastic Agents | Major topic |
| Leukemia, Large Granular Lymphocytic | Major topic |
| Aged | |
| Alemtuzumab | |
| Drug Administration Schedule | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Prospective Studies | |
| Remission Induction | |
| Treatment Outcome |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| Z99 CA999999 | Intramural NIH HHS | United States | Z99CA999999 | PubMed | NIH RePORTER |
| ZICBC011079 | NIH | NIH RePORTER |
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT00345345 | Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia | Derived from the trial | Yes |
Source ClinicalTrials.gov
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 26765647 | Alemtuzumab in T-cell large granular lymphocyte leukaemia. | https://conductscience.org/library/papers/26765647 |
Source PubMed
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17148582 | Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. | Blood | 2007 | https://conductscience.org/library/papers/17148582 | PubMed |
| 2 | 17045649 | T-cell large granular lymphocytic (T-LGL) leukemia: experience in a single institution over 8 years. | Leuk Res | 2007 | https://conductscience.org/library/papers/17045649 | PubMed |
| 3 | 19597025 | Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19597025 | PubMed |
| 4 | 19794084 | Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemia. | Haematologica | 2009 | https://conductscience.org/library/papers/19794084 | PubMed |
| 5 | 20367569 | Large granular lymphocyte leukemia: natural history and response to treatment. | Leuk Lymphoma | 2010 | https://conductscience.org/library/papers/20367569 | PubMed |
| 6 | 20211489 | Rapid and durable molecular response of refractory T-cell large granular lymphocyte leukemia after alemtuzumab treatment. | Leuk Res | 2010 | https://conductscience.org/library/papers/20211489 | PubMed |
| 7 | 21041705 | Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. | J Clin Oncol | 2010 | https://conductscience.org/library/papers/21041705 | PubMed |
| 8 | 21190991 | How I treat LGL leukemia. | Blood | 2011 | https://conductscience.org/library/papers/21190991 | PubMed |
| 9 | 21571962 | Flow cytometric immunophenotypic assessment of T-cell clonality by Vβ repertoire analysis: detection of T-cell clonality at diagnosis and monitoring of minimal residual disease following therapy. | Am J Clin Pathol | 2011 | https://conductscience.org/library/papers/21571962 | PubMed |
| 10 | 21948296 | Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. | Blood | 2011 | https://conductscience.org/library/papers/21948296 | PubMed |
| 11 | 23122652 | Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. | Lancet | 2012 | https://conductscience.org/library/papers/23122652 | PubMed |
| 12 | 22859607 | STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. | Blood | 2012 | https://conductscience.org/library/papers/22859607 | PubMed |
| 13 | 23122650 | Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. | Lancet | 2012 | https://conductscience.org/library/papers/23122650 | PubMed |
| 14 | 22067384 | Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia. | Blood | 2012 | https://conductscience.org/library/papers/22067384 | PubMed |
| 15 | 16111536 | Alemtuzumab induced complete remission of therapy-resistant pure red cell aplasia. | Leuk Res | 2005 | https://conductscience.org/library/papers/16111536 | PubMed |
| 16 | 16193089 | Remission of pure red cell aplasia in T-cell receptor gammadelta-large granular lymphocyte leukemia after therapy with low-dose alemtuzumab. | Leukemia | 2005 | https://conductscience.org/library/papers/16193089 | PubMed |
| 17 | 16795070 | T-cell large granular lymphocyte leukemia: A report on the treatment of 29 patients and a review of the literature. | Cancer | 2006 | https://conductscience.org/library/papers/16795070 | PubMed |
| 18 | 7920220 | Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues. | Leuk Lymphoma | 1994 | https://conductscience.org/library/papers/7920220 | PubMed |
| 19 | 2317110 | Phenotypic and genotypic analysis of mononuclear cells from patients with Felty's syndrome. | Ann Rheum Dis | 1990 | https://conductscience.org/library/papers/2317110 | PubMed |
| 20 | 2403836 | Clinical course and prognosis of the lymphoproliferative disease of granular lymphocytes. A multicenter study. | Cancer | 1990 | https://conductscience.org/library/papers/2403836 | PubMed |
Cited by26
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 45 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42977785 | Salvage therapy for immune-mediated bone marrow failure. | Leukemia | 2026 | https://conductscience.org/library/papers/42977785 | PubMed |
| 42706151 | [Chinese expert consensus on the diagnosis and treatment of large granular lymphocytic leukemia (2026)]. | Zhonghua Xue Ye Xue Za Zhi | 2026 | https://conductscience.org/library/papers/42706151 | PubMed |
| 41899567 | How We Evaluate and Treat Leukemic Presentations of Mature T-Cell Lymphomas. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41899567 | PubMed |
| 41580422 | CD52 signaling via macrophage Siglec-G represents a therapeutic target for cancer immunotherapy. | NPJ Breast Cancer | 2026 | https://conductscience.org/library/papers/41580422 | PubMed |
| 40342876 | Peripheral T- and natural killer-cell lymphomas: ESMO-EHA Clinical Practice Guideline for diagnosis, treatment, and follow-up. | Hemasphere | 2025 | https://conductscience.org/library/papers/40342876 | PubMed |
| 40214729 | Alemtuzumab for haematological malignancies. | Ann Hematol | 2025 | https://conductscience.org/library/papers/40214729 | PubMed |
| 40147444 | KLRG1 re-defines a leukemic clone of CD8 effector T cells sensitive to PI3K inhibitor in T cell large granular lymphocytic leukemia. | Cell Rep Med | 2025 | https://conductscience.org/library/papers/40147444 | PubMed |
| 39644019 | Large granular lymphocyte leukemia: a clonal disorder with autoimmune manifestations. | Hematology Am Soc Hematol Educ Program | 2024 | https://conductscience.org/library/papers/39644019 | PubMed |
| 39540224 | Short-course subcutaneous alemtuzumab induces clinical responses in relapsed T-cell large granular leukemia. | Haematologica | 2025 | https://conductscience.org/library/papers/39540224 | PubMed |
| 38610985 | Large Granular Lymphocytic Leukemia: Clinical Features, Molecular Pathogenesis, Diagnosis and Treatment. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38610985 | PubMed |
| 37658347 | Peripheral neuropathy associated with chronic lymphoproliferative disorders of natural killer cells (CLPD-NK): a case report and literature review. | BMC Neurol | 2023 | https://conductscience.org/library/papers/37658347 | PubMed |
| 36362180 | Molecular Features and Diagnostic Challenges in Alpha/Beta T-Cell Large Granular Lymphocyte Leukemia. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36362180 | PubMed |
| 35672859 | Large granular lymphocytic leukemia cured by allogeneic stem cell transplant: a case report. | J Med Case Rep | 2022 | https://conductscience.org/library/papers/35672859 | PubMed |
| 35411050 | Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. | Nat Commun | 2022 | https://conductscience.org/library/papers/35411050 | PubMed |
| 35411048 | Single-cell RNA sequencing coupled to TCR profiling of large granular lymphocyte leukemia T cells. | Nat Commun | 2022 | https://conductscience.org/library/papers/35411048 | PubMed |
| 35223485 | T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue? | Front Oncol | 2022 | https://conductscience.org/library/papers/35223485 | PubMed |
| 35212923 | Large Granular Lymphocytic Leukemia: Current State of Diagnosis, Pathogenesis and Treatment. | Curr Oncol Rep | 2022 | https://conductscience.org/library/papers/35212923 | PubMed |
| 35178350 | Toward a Better Classification System for NK-LGL Disorders. | Front Oncol | 2022 | https://conductscience.org/library/papers/35178350 | PubMed |
| 34685780 | Neutropenia and Large Granular Lymphocyte Leukemia: From Pathogenesis to Therapeutic Options. | Cells | 2021 | https://conductscience.org/library/papers/34685780 | PubMed |
| 34503230 | Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34503230 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| ALEMTUZUMAB | CHEMBL1201587 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1201587 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26765645
GET https://conductscience.org/api/papers/v1/26765645/authors?page=2